Showing results (131-140 of 169) with videos related to

Sort By:
Pageof 17
Clinical Lung Cancer|October 26, 2019
Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE TrialJaafar Bennouna, Nicolas Girard, Clarisse Audigier-Valette, et al.
Trials|January 20, 2023
PROPERTY: study protocol for a randomized, double-blind, multicenter placebo-controlled trial assessing neurotoxicity in patients with metastatic gastrointestinal cancer taking PHYCOCARE® during oxaliplatin-based chemotherapyChristele Le Gouill-Jaijarat, Yann Péréon, Maxime Leroy, et al.
JAMA Oncology|January 4, 2019
Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor TrialRaffit Hassan, Anish Thomas, John J Nemunaitis, et al.
British Journal of Cancer|February 5, 2020
Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trialThomas Aparicio, Jaafar Bennouna, Karine Le Malicot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2013
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsLecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, et al.
Cancer|November 2, 2018
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC)Daniel Morgensztern, Manuel Cobo, Santiago Ponce Aix, et al.
Seminars in Oncology|April 12, 2017
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approachMichele Boisdron-Celle, Olivier Capitain, Roger Faroux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2025
Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece TrialsJulien Taieb, John Souglakos, Ioannis Boukovinas, et al.
Targeted Oncology|March 13, 2025
Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS StudyJean Mourlanette, Gaelle Rousseau-Bussac, Siham Mallah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2023
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> MutationsLecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, et al.
Pageof 17